Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

You may also be interested in...

Manufacturers Unable to Make Minor Changes to Products in China

A lack of a reporting mechanism for minor or moderate changes to approved pharmaceuticals in China makes it difficult for pharmaceutical manufacturers to make lifecycle improvements to products marketed there. Long review timelines and unclear expectations during inspections further complicate the picture.

A Closer Look: With Only 60% Of China’s Sterile Drug Makers Passing New GMP Standard, What’s Next?

Only 60% of sterile drug manufacturers passed the new GMP standard in China, as smaller companies chose to quit the market.

China FDA Bans Korean Drug After Disagreement On Overseas Inspection

In a sign of increasing confidence by Chinese regulators, CFDA banned an injectable antibiotic from Daewoong Pharmaceutical after the company rejected an overseas inspection request due to ongoing upgrades at a Korean plant.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts